Canada - English
Canada - Français
For a refined risk estimateof local recurrence
Primary study group results were presented at ASCO 2018.
Help Stage II colon cancer patients understand the power of genomics
In a large clinical data setGPS increased AS utilzation
Nuclear-specific vs. nuclear-agnostic AR-V7 testing
Your Oncotype DX score can help you decide.
Oncotype DX has helped thousands of women find out.
When Dan's Colon Recurrence Score came back low, he decided against chemotherapy.
Read what the Wall Street Journal is saying about the Oncotype DX Genomic Prostate Score test.
Join us at our symposium about using the Recurrence Score result to help guide adjuvant treatment decisions.
Clinical Director, Breast Medicine Service
Section Head, Triple Negative Breast Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center
Associate Professor, Weill Cornell Medical College
Senior Director, Medical Affairs,
Exhibit Hall – Product Theater, Lunch Provided
Henry B. Gonzalez Convention Center, San Antonio, TX
Sparano: What would Bill think? Special Session
McGuire Memorial Lecture | 11:15 AM-12 PM | Hall 3
Bar-Sela: Ethnicity, Recurrence Score distribution, and clinical outcomes in ER+ HER2− breast cancer patients in Israel
Poster Session 1 | 5-7 PM | Hall 1
Petkov: Breast cancer-specific mortality in patients age 50 years or younger with node-positive breast cancer treated based on the 21-gene assay in clinical practice
Poster Session 3 | 5-7 PM | Hall 1
Wei: Use of Oncotype DX DCIS for disease management in a prospective DCIS registry
Poster Session OT3 | 5-7 PM | Hall 1
Rakovitch: Impact of a multigene expression assay combined with clinicopathological features on radiotherapy recommendation in patients with low/intermediate risk DCIS treated with breast-conserving surgery
Poster Session 6 | 7-9 AM | Hall 1
Have a specific question? Want to keep up with our latest news? We're here for you.